DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome.

Author(s): Garcia-Borreguero D(1), Patrick J(2), DuBrava S(2), Becker PM(3), Lankford A(4), Chen C(2), Miceli J(2), Knapp L(2), Allen RP(5).

Affiliation(s): Author information: (1)Sleep Research Institute, Madrid, Spain. (2)Pfizer Global Research and Development, Groton, CT. (3)University of Texas Southwestern Medical Center, Dallas, TX. (4)Sleep Disorders Center of Georgia, Atlanta, GA. (5)Johns Hopkins University, Department of Neurology, Baltimore, MD.

Publication date & source: 2014, Sleep. , 37(4):635-43

STUDY OBJECTIVES: To compare pregabalin versus placebo and pramipexole for reducing restless legs syndrome (RLS)-related sleep disturbance. DESIGN: Randomized, double-blinded, crossover trial. SETTING: Twenty-three US sleep centers. PARTICIPANTS: Eighty-five individuals with moderate to severe idiopathic RLS and associated sleep disturbance. INTERVENTIONS: Participants were randomized across 6 treatment sequences comprising three 4-week periods on pregabalin 300 mg/day (n = 75), pramipexole 0.5 mg/day (n = 76), or placebo (n = 73). MEASUREMENTS AND RESULTS: Polysomnography was conducted over 2 nights at the end of each period. Primary (wake after sleep onset [WASO], pregabalin vs placebo) and key secondary endpoints were analyzed for statistical significance, with descriptive statistics for other endpoints. Pregabalin improved sleep maintenance, demonstrated by reductions in WASO (-27.1 min vs placebo [P < 0.0001]; -26.9 vs pramipexole) and number of awakenings after sleep onset (-2.7 vs placebo; -7.9 vs pramipexole [P < 0.0001]) by polysomnography, and an increase in subjective total sleep time (30.8 min vs placebo [P < 0.0001]; 26.8 vs pramipexole). Pregabalin also increased slow wave sleep duration (20.9 min vs placebo; 32.1 vs pramipexole [P < 0.0001]). Reduction in periodic limb movement arousal index (PLMAI) with pregabalin was similar to pramipexole and greater than placebo (-3.7 PLMA/h [P < 0.0001]), although reduction in total PLM in sleep was less than for pramipexole. CONCLUSIONS: This study demonstrated improvements in objective and subjective measures of sleep maintenance and sleep architecture with pregabalin compared with placebo and pramipexole. Effects of pregabalin on periodic limb movement arousal index were comparable to pramipexole. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT00991276; http://clinicaltrials.gov/show/NCT00991276.

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017